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Abstract
BACKGROUND—Patients with chronic infection with hepatitis C virus (HCV) genotype 1 often
need 48 weeks of peginterferon–ribavirin treatment for a sustained virologic response. We
designed a noninferiority trial (noninferiority margin, −10.5%) to compare rates of sustained
virologic response among patients receiving two treatment durations.
METHODS—We enrolled patients with chronic infection with HCV genotype 1 who had not
previously received treatment. All patients received telaprevir at a dose of 750 mg every 8 hours,
peginterferon alfa-2a at a dose of 180 μg per week, and ribavirin at a dose of 1000 to 1200 mg per
day, for 12 weeks (T12PR12), followed by peginterferon–ribavirin. Patients who had an extended
rapid virologic response (undetectable HCV RNA levels at weeks 4 and 12) were randomly
assigned after week 20 to receive the dual therapy for 4 more weeks (T12PR24) or 28 more weeks
(T12PR48). Patients without an extended rapid virologic response were assigned to T12PR48.
RESULTS—Of the 540 patients, a total of 352 (65%) had an extended rapid virologic response.
The overall rate of sustained virologic response was 72%. Among the 322 patients with an
extended rapid virologic response who were randomly assigned to a study group, 149 (92%) in the
T12PR24 group and 140 (88%) in the T12PR48 group had a sustained virologic response
(absolute difference, 4 percentage points; 95% confidence interval, −2 to 11), establishing
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noninferiority. Adverse events included rash (in 37% of patients, severe in 5%) and anemia (in
39%, severe in 6%). Discontinuation of all the study drugs was based on adverse events in 18% of
patients overall, as well as in 1% of patients (all of whom were randomly assigned) in the
T12PR24 group and 12% of the patients randomly assigned to the T12PR48 group (P<0.001).
CONCLUSIONS—In this study, among patients with chronic HCV infection who had not
received treatment previously, a regimen of peginterferon–ribavirin for 24 weeks, with telaprevir
for the first 12 weeks, was noninferior to the same regimen for 48 weeks in patients with
undetectable HCV RNA at weeks 4 and 12, with an extended rapid virologic response achieved in
nearly two thirds of patients. (Funded by Vertex Pharmaceuticals and Tibotec; ILLUMINATE
ClinicalTrials.gov number, NCT00758043.)
Chronic infection with hepatitis c virus (HCV) represents a serious health issue for nearly
200 million infected persons worldwide.1 Achievement of a sustained virologic response
may be associated with improved long-term clinical outcomes, including increased
survival.2,3 In patients infected with HCV genotype 1, 48 weeks of treatment with
peginterferon alfa and ribavirin results in a rate of sustained virologic response of 40 to
50%.4,5
Telaprevir administered in combination with peginterferon and ribavirin has led to high rates
of sustained virologic response in phase 2 and phase 3 trials involving patients with HCV
genotype 1 infection, who have not previously received treatment, in the United States and
Europe.6–8 Telaprevir is an orally bioavailable inhibitor of the nonstructural 3/4A (NS3/4A)
HCV protease. Phase 2 data have suggested that a high proportion of patients have a rapid
decline in viral levels during early treatment stages and that a response-guided treatment
regimen based on viral response may permit a shorter treatment duration while preserving
high rates of sustained virologic response. Such a strategy may decrease the risk of exposure
of patients to not only potential side effects from telaprevir but also to the well-characterized
adverse events associated with the 48-week use of peginterferon and ribavirin.
In this multinational, randomized study, we assessed the efficacy and safety of response-
guided therapy consisting of a three-drug regimen of telaprevir, peginterferon alfa-2a, and
ribavirin in patients with chronic HCV genotype 1 infection who had not previously
received treatment. The primary goal was to assess the noninferiority of a 24-week versus a
48-week telaprevir-based regimen among patients who had an extended rapid virologic
response (undetectable HCV RNA levels at weeks 4 and 12).
METHODS
STUDY PATIENTS
Eligible patients were enrolled at 74 sites in Belgium, the Netherlands, and the United States
(including Puerto Rico). Inclusion criteria for enrollment were the presence of chronic
infection with HCV genotype 1, indicated by a diagnosis at more than 6 months before the
screening visit, with a detectable HCV RNA level at the visit, as well as no previous
treatment for HCV infection; age between 18 and 70 years; seronegative test for hepatitis B
virus and human immunodeficiency virus; an absolute neutrophil count of 1500 or more per
cubic millimeter; a platelet count of 90,000 or more per cubic millimeter; and a hemoglobin
level of 12 g or more per deciliter for female patients and 13 g or more per deciliter for male
patients. All patients had undergone a liver biopsy within 1 year before the screening visit or
underwent the procedure during the screening period unless a biopsy more than 1 year
previously showed evidence of cirrhosis. Patients with hepatic decompensation, clinically
significant liver disease from another cause, or active cancer within the previous 5 years
(except treated basal-cell carcinoma) were excluded.
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STUDY DESIGN AND CONDUCT
All patients provided written informed consent. The study was approved by the institutional
review boards of all study centers and was performed in accordance with Good Clinical
Practice guidelines as defined by the International Conference on Harmonization and the
Declaration of Helsinki. The study protocol and statistical analysis plan are available with
the full text of this article at NEJM.org.
Vertex Pharmaceuticals and Tibotec funded the study. The academic principal investigator
participated in study design and protocol development with the study sponsors, had
unrestricted access to the data, prepared the first draft of the manuscript, and made the
decision to submit the manuscript for publication. All authors reviewed and approved the
final manuscript and assume responsibility for the accuracy and completeness of the data
reported. An employee of Vertex Pharmaceuticals provided medical writing, editorial, and
coordination services.
The ILLUMINATE (Illustrating the Effects of Combination Therapy with Telaprevir) trial
was an open-label, randomized, phase 3 noninferiority trial in which the results of HCV
RNA testing were double-blinded through week 24. All patients received triple therapy for
12 weeks, consisting of telaprevir (Vertex Pharmaceuticals) at a dose of 750 mg orally every
8 hours, peginterferon alfa-2a (40 kD) (Pegasys, Roche) at a dose of 180 μg injected
subcutaneously once weekly, and ribavirin (Copegus, Roche) at a dose of 1000 mg per day
for patients weighing less than 75 kg or 1200 mg per day for patients weighing 75 kg or
more. After 12 weeks, all patients continued to receive peginterferon–ribavirin only.
ASSESSMENT OF EFFICACY
At study visits, the HCV RNA level was measured with the use of the COBAS TaqMan
assay (Roche Molecular Systems, version 2.0), which has a lower limit of quantification of
25 IU per milliliter and a lower limit of detection of approximately 10 to 15 IU per milliliter.
After the week 20 visit, patients who had had an undetectable HCV RNA level at week 4
and week 12 (i.e., an extended rapid virologic response) were randomly assigned, in a 1:1
ratio, to stop treatment at week 24 (the T12PR24 group) or to continue peginterferon–
ribavirin therapy through 48 weeks (the T12PR48 group). Randomization was centrally
managed, blocked, and stratified to optimize balance with regard to HCV genotype subtype
(1a, 1b, or unknown) and self-reported race (black or nonblack). Patients who had not had
an extended rapid virologic response were nonrandomly assigned to the T12PR48 group.
Upon the completion of treatment, all patients entered the follow-up phase, consisting of 48
weeks for the T12PR24 group and 24 weeks for the T12PR48 group. Patients who
discontinued treatment before randomization were also followed for 24 weeks. All patients
were assessed for a sustained virologic response at 24 weeks of follow-up and, in patients in
the T12PR24 group, at 48 weeks of follow-up. All patients who completed the follow-up
period were assessed for a response to treatment.
Virologic failure was defined as an HCV RNA level greater than 1000 IU per milliliter at
week 4, a decline from baseline by less than 2 log10 units in the level of detectable HCV
RNA at week 12, or a detectable HCV RNA level at any time between weeks 24 and 36.
According to the study protocol, telaprevir was stopped in patients with an HCV RNA level
greater than 1000 IU per milliliter at week 4, and all study drugs were stopped in patients
who had virologic failure at week 12 or between weeks 24 and 36.
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Samples for sequence-based virologic assessment of changes in the NS3/4A coding domain
were collected at baseline. These were compared with samples obtained during the study for
patients in whom HCV RNA did not become undetectable.
SAFETY
Planned safety evaluations included physical examinations, laboratory evaluation of key
safety variables, and adverse-event reporting according to the Division of Acquired
Immunodeficiency Syndrome (DAIDS) criteria for the assessment of severity. For adverse
events not listed in the DAIDS criteria, severity assessment was based on protocol-defined
criteria. Electrocardiography was performed at baseline. During the first 12 weeks of the
study, investigators could discontinue the use of telaprevir (while continuing to administer
peginterferon–ribavirin) if serious adverse events potentially attributable to telaprevir were
observed. These included, but were not restricted to, rash and anemia. The use of
erythropoietin or other hematopoietic growth factors was prohibited per the final amended
protocol, as were reductions of telaprevir dose.
Planned reviews of safety data were conducted by an independent data and safety
monitoring committee to evaluate the safety and tolerability of the study-drug regimens. A
statistical group independent of the sponsors performed the analyses and safety-data
preparation for each review.
STATISTICAL ANALYSIS
The primary efficacy variable was a sustained virologic response, defined as an undetectable
HCV RNA level at the end of the treatment phase and 24 weeks after the last planned dose
of study medication. The primary analysis was the estimation of the difference in sustained
virologic response between patients who had extended rapid virologic response and were
randomly assigned to receive T12PR24 versus T12PR48. The sample size was chosen to
permit a noninferiority comparison between these two randomized subgroups with a
predefined noninferiority margin of −10.5%. A sample size of 157 randomly assigned
patients per study group was estimated to have 80% power to rule out the noninferiority of
T12PR24 as compared with T12PR48 if the observed rate of sustained virologic response
was 90%.
RESULTS
BASELINE CHARACTERISTICS OF THE STUDY PATIENTS
A total of 540 patients received at least one dose of a study drug (Fig. 1) and represent the
overall study population (Table 1). Black race was self-reported in 73 patients (14%); 54
patients (10%) identified themselves as Hispanic or Latino; and 3 (1%) identified
themselves as black and Hispanic or Latino. A total of 149 patients (28%) had bridging
fibrosis or cirrhosis. Genotype subtype 1a was predominant (388 patients [72%]).
EFFICACY AND NONINFERIORITY
Overall, 72% (389 of 540) of the study patients had a rapid virologic response, defined as
undetectable HCV RNA at week 4; 65% (352 of 540) had an extended rapid virologic
response. One hundred patients, including 30 who had an extended rapid virologic response,
discontinued the study drugs owing to adverse events, withdrawal of consent, or other
reasons. The overall rate of sustained virologic response was 72% (Table 2). Of the 322
patients who had an extended rapid virologic response and a week 20 visit, 162 were
randomly assigned to the T12PR24 group, of whom 149 (92%) had a sustained virologic
response; and 160 were randomly assigned to the T12PR48 group, of whom 140 (88%) had
a sustained virologic response. A total of 118 patients who had not had an extended rapid
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virologic response were assigned to the T12PR48 group, and 76 (64%) had a sustained
virologic response. Of the remaining 100 patients, who prematurely discontinued treatment
before week 20, 23 (23%) had a sustained virologic response.
The primary study objective was the noninferiority of the T12PR24 regimen to the T12PR48
regimen; specifically, the rate of sustained virologic response among patients with an
undetectable HCV RNA level at weeks 4 and 12 who were randomly assigned to 24-week
versus 48-week treatment. The majority of patients (99%) in the 24-week group completed
the treatment, as compared with 74% in the 48-week group (P<0.001). The absolute
difference in the rate of sustained virologic response between the T12PR24 group and the
T12PR48 group was 4 percentage points (95% confidence interval [CI], −2 to 11). The
lower limit of this 95% CI (−2%) excluded the noninferiority margin of −10.5%.
Low rates of relapse were observed after the completion of treatment (6% with T12PR24
and 3% with T12PR48), with an overall relapse rate of 8% (Table 2). The HCV RNA level
was undetectable at 72 weeks after the start of treatment in 70% (377 of 540) of patients
overall, with an absolute difference of −0.5 percentage points between the T12PR24 group
(87.0%) and the patients in the T12PR48 group who had had an extended rapid virologic
response (87.5%) (95% CI, −7.7 to 6.8).
Rates of response in subgroups with host or baseline characteristics that have been
historically associated with poor treatment outcome were also examined. Overall, 69% of
patients with a high viral load (≥800,000 IU per milliliter) had a sustained virologic
response. Among those with an extended rapid virologic response, HCV RNA levels at
baseline were not a predictor of a sustained virologic response, which was achieved in
nearly 90% of patients with high viral load. Similarly, genotype subtype (1a vs. 1b) did not
affect the treatment outcome, either in the overall population or among randomly assigned
patients (Table 2). In all, 63% of patients with bridging fibrosis or cirrhosis had a sustained
virologic response. Among patients with an extended rapid virologic response and bridging
fibrosis or cirrhosis, rates of sustained virologic response were 82% in the T12PR24 group
and 88% in the T12PR48 group (Table 2). This difference was not significant. Overall, 74%
of white patients versus 60% of black patients had a sustained virologic response (P=0.02)
(Table 2). Neither race nor ethnic group was associated with any decrease in the rate of
sustained virologic response among the patients who had had an extended rapid virologic
response; no significant differences were observed between the two randomized subgroups.
VIROLOGIC FAILURE AND TELAPREVIR-RESISTANT VARIANTS
Virologic failure during the treatment phase, including in patients who met the stopping
rules and had detectable HCV RNA levels at the end of treatment, was uncommon, found in
8% of the overall population and in 2% of patients in the T12PR24 group and 3% of the
patients in the T12PR48 group who had had an extended rapid virologic response (P=0.22).
HCV variants with decreased sensitivity to telaprevir were observed in the majority of
patients in whom HCV RNA did not become undetectable, including the previously
described variants with NS3/4A positions 36, 54, 155, and 156.9 Follow-up of patients
without a sustained virologic response showed that 55% of those with resistant variants at
the time of treatment failure no longer had them (as detected by means of population
sequencing) at their last visit (median follow-up, 43 weeks).
SAFETY AND SIDE-EFFECT PROFILE
In the overall treatment phase, 9% of patients had serious adverse events, anemia being the
most common, reported in 2% of patients (Table 3). A total of 2% of patients in the
T12PR24 group, as compared with 10% of the patients in the T12PR48 group who had had
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an extended rapid virologic response, had serious adverse events (P = 0.005). Fatigue was
the most common adverse event (68%), followed by pruritus (51%), nausea (47%), anemia
(39%), headache (38%), rash (37%), insomnia (34%), diarrhea (30%), and influenza-like
illness (26%).
During the telaprevir treatment phase (i.e., the first 12 weeks), 7% of all patients
discontinued all study drugs, with 1% attributable to rash events and 1% to anemia events.
Twelve percent of patients discontinued telaprevir only, owing to adverse events, with 7%
due to rash events and 2% to anemia events (Table 3).
Roughly two thirds of the observed rashes occurred in the first 8 weeks. Rashes were
primarily eczematous in nature and were typically treated with topical medications (e.g.,
topical glucocorticoids or antihistamines), oral antihistamines, or both. Severe rash occurred
in 5% of patients and was managed by means of discontinuation of telaprevir first, with
continuation of peginterferon–ribavirin; if the rash did not improve within 7 days after
telaprevir discontinuation, ribavirin (with or without peginterferon) was to be either
interrupted or discontinued.
Severe anemia was reported in 6% of patients. During the treatment phase, 14 patients had
low hemoglobin levels (<7 g per deciliter), classified as a grade 4 adverse event, with 11 of
the 14 going on to have a sustained virologic response. A total of 32 patients received blood
transfusions for treatment of anemia during the study; 7 patients (1%) received an
erythropoiesis-stimulating agent, and a sustained virologic response was achieved in 6 of
these 7. The ribavirin dose was modified in 46% of patients because of decreased
hemoglobin levels. A total of 73% of the patients whose ribavirin dose was not modified had
a sustained virologic response, as did 68% and 75% of patients who had at least one dose
reduction and at least one dose reduction and interruption, respectively. Among all study
patients, 18% discontinued all study drugs because of adverse events, including 1% of the
patients in the T12PR24 group and 12% of the patients in the T12PR48 group who had had
an extended rapid virologic response (P<0.001) (Table 3).
DISCUSSION
We found that a 24-week treatment regimen of peginterferon–ribavirin, with telaprevir
added for the first 12 weeks, was noninferior to a 48-week regimen of peginterferon–
ribavirin, with telaprevir added for the first 12 weeks in patients with chronic infection with
HCV genotype 1 who have not received treatment previously and who had an extended
rapid virologic response. Nearly two thirds of the enrolled patients met this definition and
were eligible for an abbreviated course of therapy. Thus, this study supports the concept of
response-guided therapy. Relapse rates were low and were not significantly different
between the 24-week group and the 48-week group. The sustained virologic response among
all study patients was 72%.
Telaprevir-based therapy guided by the presence or absence of an extended rapid virologic
response selected for a population that demonstrated uniformly high rates of sustained
virologic response regardless of race, ethnic group, or presence or absence of advanced
fibrosis. There were high rates of response among blacks (60%) and Hispanics or Latinos
(67%), in contrast with the historically poor responses in these subgroups reported in large
published trials. The Viral Resistance to Antiviral Therapy of Chronic Hepatitis C study
(VIRAHEP-C; ClinicalTrials.gov number, NCT00038974) reported a sustained virologic
response of 28% among blacks receiving peginterferon–ribavirin.10 Response rates among
patients with bridging fibrosis or cirrhosis were high; however, few patients had cirrhosis in
our study, and further investigation is warranted.
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Virologic failure was frequently associated with the appearance of mutations related to
resistance to telaprevir and other class-specific serine protease inhibitors. Follow-up of
patients without a sustained virologic response in our study showed that 55% of patients
who originally had resistant variants no longer had resistant variants at their last visit
(median follow-up, 43 weeks). In addition, long-term follow-up of patients who had
virologic failure in phase 2 telaprevir studies showed that in 89% of patients, telaprevir-
resistant variants were no longer detectable after a median follow-up time of 22 months, on
the basis of population sequencing.11
Rates of drug discontinuation were similar to those in other clinical trials of telaprevir-based
therapy6–8 and were slightly higher than those observed in pivotal trials of peginterferon–
ribavirin only.4,5 The overall incidences of rash (37%) and severe rash (5%) were similar to
those in the 12-week telaprevir-based treatment groups in the ADVANCE (A New Direction
in HCV Care: A Study of Treatment-Naive Hepatitis C Patients with Telaprevir) trial
(NCT00627926) (37% and 6%, respectively).8 Although rash was common in our study, it
was usually mild and was a relatively infrequent cause of discontinuation of all study
medications. Our protocol differed from earlier phase 2 trials of telaprevir in that
investigators were permitted to discontinue administration of telaprevir, in cases of severe or
worsening rash, while maintaining the administration of peginterferon–ribavirin. Since most
of these discontinuations occurred after HCV was undetectable (i.e., after 8 weeks of
treatment), the discontinuation of telaprevir did not negatively affect the rate of sustained
virologic response.
The incidence of anemia in our study (39%) was similar to that in the 12-week telaprevir-
based groups in ADVANCE (37%).8 Rates of discontinuation of telaprevir and all study
drugs owing to anemia-associated events were low. High rates of sustained virologic
response were observed despite ribavirin-dose modifications, as well as in the small number
of patients who received an erythropoiesis-stimulating agent.
In our phase 3 study, 24 weeks of peginterferon and ribavirin treatment was noninferior to
48 weeks of treatment for patients infected with HCV genotype 1 who had not previously
received treatment and who had undetectable HCV RNA levels at weeks 4 and 12. This
response-guided regimen resulted in a shorter treatment duration with high rates of sustained
virologic response for approximately two thirds of treated patients. The treatment regimen
was highly effective in patients with a historically poor treatment response, including blacks,
patients with bridging fibrosis or cirrhosis, and patients with high HCV RNA levels.
Response-guided therapy also resulted in decreased rates of adverse events and treatment
discontinuation among patients who received treatment over the shorter period.
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Figure 1. Enrollment, Randomization or Assignment, and Follow-up of the Study Patients
Virologic failure was defined as an HCV RNA level greater than 1000 IU per milliliter at
week 4, a decline from baseline by less than 2 log10 units in the level of detectable HCV
RNA at week 12, or a detectable HCV RNA level at any time between weeks 24 and 36.
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Table 1
Baseline Characteristics of the Study Patients, According to Study Group.*
Characteristic
Randomly Assigned
to T12PR24 (N =
162)
Randomly Assigned
to T12PR48 (N =
160)
Nonrandomly Assigned
to T12PR48 (N = 118)
Discontinued
Treatment before Wk
20 (N = 100)
Age — yr
 Median 51 50 51 52
 Range 22–70 19–67 20–63 21–66
Body-mass index†
 Median 28 27 27 27
 Range 18–53 19–49 19–54 19–44
 Distribution
  <25 44 (27) 60 (38) 35 (30) 38 (38)
　 ≥25 to <30 56 (35) 51 (32) 49 (42) 32 (32)
　 ≥30 61 (38) 49 (31) 34 (29) 30 (30)
  Missing data 1 (1) 0 0 0
Male sex — no. (%) 104 (64) 97 (61) 70 (59) 54 (54)
Race — no. (%)‡
 White 135 (83) 131 (82) 86 (73) 75 (75)
 Black 17 (10) 17 (11) 20 (17) 19 (19)
 Other 10 (6) 12 (8) 12 (10) 6 (6)
Hispanic or Latino ethnic group — no. (%)‡
 Yes 18 (11) 11 (7) 8 (7) 17 (17)
 No 140 (86) 146 (91) 105 (89) 82 (82)
 Missing data 4 (2) 3 (2) 5 (4) 1 (1)
HCV genotype 1 subtype — no. (%)§
 1a 115 (71) 117 (73) 84 (71) 72 (72)
 1b 46 (28) 43 (27) 33 (28) 27 (27)
 Unknown 1 (1) 0 1 (1) 1 (1)
HCV RNA log10 — IU/ml¶ 6.3±0.9 6.4±0.7 6.7±0.6 6.4±0.7
HCV RNA level ≥800,000 IU/ml
— no. (%)¶
124 (77) 126 (79) 108 (92) 87 (87)
Stage of fibrosis and cirrhosis — no. (%)
 None or minimal fibrosis 46 (28) 48 (30) 27 (23) 26 (26)
 Portal fibrosis 78 (48) 79 (49) 49 (42) 38 (38)
 Bridging fibrosis 20 (12) 21 (13) 30 (25) 17 (17)
 Cirrhosis 18 (11) 12 (8) 12 (10) 19 (19)
*
Plus–minus values are means ±SD. None of the characteristics differed significantly between the randomized groups (P>0.05 for all
comparisons). Patients received telaprevir (750 mg every 8 hours) for 12 weeks, as well as peginterferon alfa-2a (180 μg per week) and ribavirin
(1000 or 1200 mg per day, according to body weight) for a total of either 24 weeks (T12PR24) or 48 weeks (T12PR48). Patients who had an
extended rapid virologic response were randomly assigned to either the T12PR24 group or the T12PR48 group. Patients who did not have an
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extended rapid virologic response were nonrandomly assigned to the T12PR48 group. The remaining patients discontinued the treatment regimen
before week 20 or nonrandom assignment. HCV denotes hepatitis C virus.
†
The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡
Race and ethnic group were self-reported and were not mutually exclusive. The “other” race category included patients self-identifying as Asian,
American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, or other self-reported races, as well as 13 patients for whom local
regulations did not permit asking about race or ethnic group.
§
HCV genotype and subtype were ascertained by means of line-probe assay (Inno-LiPA, Innogenetics).
¶
HCV RNA levels were measured with the use of the COBAS TaqMan HCV assay (Roche Molecular Systems), which has a lower limit of
quantification of 25 IU per milliliter and a lower limit of detection of approximately 10 to 15 IU per milliliter.
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